Table 4.
All subjects (N = 18279) | AKI stage 1 (N = 5557) | AKI stage 2 (N = 6798) | AKI stage 3 (N = 5924) | |||||
---|---|---|---|---|---|---|---|---|
AUC (95% CI) | P | AUC (95% CI) | P | AUC (95% CI) | P | AUC (95% CI) | P | |
RDW | 0.718 (0.712–0.725) | 0.713 (0.701–0.725) | 0.684 (0.673–0.695) | 0.757 (0.746–0.768) | ||||
APS III | 0.706 (0.700–0.713) | <0.01 | 0.682 (0.670–0.695) | <0.01 | 0.675 (0.664–0.686) | 0.297 | 0.755 (0.744–0.766) | 0.781 |
RDW + APS III | 0.758 (0.752–0.764) | <0.01 | 0.741 (0.729–0.752) | <0.01 | 0.725 (0.714–0.735) | <0.01 | 0.802 (0.792–0.812) | <0.01 |
MLODS | 0.659 (0.652–0.666) | <0.01 | 0.660 (0.647–0.672) | <0.01 | 0.608 (0.596–0.619) | <0.01 | 0.709 (0.698–0.721) | <0.01 |
RDW + MLODS | 0.741 (0.735–0.748) | <0.01 | 0.734 (0.722–0.745) | <0.01 | 0.700 (0.689–0.711) | <0.01 | 0.787 (0.776–0.797) | <0.01 |
SOFA | 0.638 (0.631–0.645) | <0.01 | 0.633 (0.620–0.646) | <0.01 | 0.586 (0.574–0.597) | <0.01 | 0.695 (0.683–0.707) | <0.01 |
RDW + SOFA | 0.732 (0.726–0.739) | <0.01 | 0.724 (0.712–0.736) | <0.01 | 0.689 (0.678–0.700) | 0.115 | 0.780 (0.769–0.791) | <0.01 |
OASIS | 0.642 (0.635–0.649) | <0.01 | 0.590 (0.577–0.603) | <0.01 | 0.643 (0.631–0.654) | <0.01 | 0.691 (0.679–0.702) | <0.01 |
RDW + OASIS | 0.750 (0.743–0.756) | <0.01 | 0.726 (0.714–0.738) | <0.01 | 0.727 (0.717–0.738) | <0.01 | 0.792 (0.781–0.802) | <0.01 |
SIRS | 0.522 (0.514–0.529) | <0.01 | 0.506 (0.493–0.519) | <0.01 | 0.510 (0.498–0.522) | <0.01 | 0.554 (0.542–0.567) | <0.01 |
RDW + SIRS | 0.720 (0.713–0.726) | 0.080 | 0.713 (0.701–0.725) | 0.964 | 0.685 (0.674–0.696) | 0.402 | 0.760 (0.749–0.771) | 0.018 |
Note: AKI, acute kidney injury; AUC, area under curve; CI, confidence interval; SE, standard error; RDW, red blood cell distribution width; APS III, acute physiology and chronic health evaluation III; MLODS, modified logistic organ dysfunction system; SOFA, sequential organ failure assessment; OASIS, Oxford acute severity of illness score; SIRS, systemic inflammatory response syndrome.